Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).
Ulrik CS.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2015.1100171 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för ritropirronium bromide. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
23 hitsCost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden.
Costa-Scharplatz M, Ställberg B, Goyal P, Asukai Y, Gruenberger JB, Price D.
Appl Health Econ Health Policy · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1007/s40258-015-0193-2Optimization of ion-pair formation between glycopyrronium bromide and different ion-pair agents using ACE.
Darwish KA, Mrestani Y, Neubert RH.
Electrophoresis · journal article · DOI 10.1002/elps.201500175Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Horita N, Kaneko T.
Int J Chron Obstruct Pulmon Dis · meta-analysis; review-article; review; journal article · DOI 10.2147/copd.s56067Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E, Montagni M, Riario-Sforza GG, Baroni M, Incorvaia C.
Ther Adv Respir Dis · review; journal article · DOI 10.1177/1753465815572065Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.
Montuschi P, Ciabattoni G.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm5013227Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Prakash A, Babu KS, Morjaria JB.
Int J Chron Obstruct Pulmon Dis · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.2147/copd.s67758Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
Riario-Sforza GG, Ridolo E, Riario-Sforza E, Incorvaia C.
Expert Rev Respir Med · review; journal article · DOI 10.1586/17476348.2015.996133The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.
Gavaldà A, Ramos I, Carcasona C, Calama E, Otal R, Montero JL, Sentellas S, Aparici M, Vilella D, Alberti J, Beleta J, Miralpeix M.
Pulm Pharmacol Ther · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.pupt.2014.05.005The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients.
Sanguinetti CM.
Multidiscip Respir Med · review-article; journal article · DOI 10.1186/2049-6958-9-19Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
Ulrik CS.
Int J Chron Obstruct Pulmon Dis · systematic review; review-article; journal article · DOI 10.2147/copd.s60362Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases.
Alagha K, Palot A, Sofalvi T, Pahus L, Gouitaa M, Tummino C, Martinez S, Charpin D, Bourdin A, Chanez P.
Ther Adv Chronic Dis · review-article; review; journal article · DOI 10.1177/2040622313518227Inhalation of glycopyrronium inhibits cigarette smoke-induced acute lung inflammation in a murine model of COPD.
Shen LL, Liu YN, Shen HJ, Wen C, Jia YL, Dong XW, Jin F, Chen XP, Sun Y, Xie QM.
Int Immunopharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.intimp.2013.12.021Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.
Bartels C, Looby M, Sechaud R, Kaiser G.
Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/bcp.12118Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies.
D'Urzo A, Kerwin E, Overend T, D'Andrea P, Chen H, Goyal P.
Curr Med Res Opin · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1185/03007995.2013.858618[New therapeutic choice for COPD: glycopyrronium bromide, a long-acting muscarinic antagonist].
Yoshisue H, Kozawa M, Hiratsuka M, Nakanishi M.
Nihon Yakurigaku Zasshi · review; journal article · DOI 10.1254/fpj.142.190Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.
Molimard M, D'Andrea P.
Expert Rev Clin Pharmacol · research support, non-u.s. gov't; review; journal article · DOI 10.1586/17512433.2013.828419Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD.
D'Urzo A.
Ther Clin Risk Manag · review-article; journal article · DOI 10.2147/tcrm.s30317[Glycopyrronium bromide is a long-acting inhaled anticholinergic in the treatment of severe COPD].
Ulrik CS.
Ugeskr Laeger · review; journal article; english abstractInhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.
Carter NJ.
Drugs · review; journal article · DOI 10.1007/s40265-013-0058-7A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
Arievich H, Overend T, Renard D, Gibbs M, Alagappan V, Looby M, Banerji D.
BMC Pulm Med · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1186/1471-2466-12-74Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.
Buhl R, Banerji D.
Int J Chron Obstruct Pulmon Dis · review-article; review; journal article · DOI 10.2147/copd.s36001Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit.
Ulrik CS.
Int J Chron Obstruct Pulmon Dis · systematic review; review-article; journal article · DOI 10.2147/copd.s35990